Viruses use mimicry to hijack cellular machinery, but can human cells use mimicry as an antiviral approach? Batra et al. identify a novel antiviral restriction factor, RBBP6, by characterizing the cellular interactome of Ebola virus. RBBP6 targets the Ebola virus transcription factor VP30 by mimicking the binding of Ebola virus nucleoprotein.
Mimicry is a common strategy for a virus to hijack cellular machinery for its own benefit. For example, large DNA viruses often encode homologs of cytokines, chemokines, and their receptors to evade the immune response (Alcami, 2003) . Likewise, RNA viruses also employ decoy strategies. Influenza virus possesses a histone-like sequence to suppress cellular antiviral response (Marazzi et al., 2012) , while HIV possesses a HEXIM RNA-binding domain mimic and a 7SK RNA mimic to hijack the cellular transcription elongation factor P-TEFb (Pham et al., 2018) . In contrast, it has been unclear whether human cells can use mimicry of viral proteins as an antiviral approach. In this issue of Cell, Batra et al. (2018) show that the ubiquitin ligase RBBP6 encoded by human cells mimics the Ebola virus nucleoprotein (NP) and binds to the Ebola virus transcription factor VP30.
Batra et al. initially determine the interaction between RBBP6 and VP30 from their interactome analysis of six Ebola virus proteins (NP, VP35, VP40, GP, VP30, and VP24) in two human cell lines, HEK293T (embryonic kidney cells) and Huh7 (human liver cells). The authors perform interactome analysis using affinity tag-purification mass spectrometry (Jean Beltran et al., 2017) and find RBBP6 to be a top hit among all VP30 interactions in both HEK293T and Huh7 cells. X-ray crystallographic analysis demonstrates that binding of VP30 to RBBP6 is highly similar to that of VP30 to NP. Both RBBP6 and NP encode a motif PPxPxY that interacts with VP30. Since the interaction between VP30 and NP is important for Ebola viral RNA synthesis (Kirchdoerfer et al., 2016; Xu et al., 2017) , RBBP6 performs its antiviral effect through hampering the Ebola viral RNA synthesis ( Figure 1 ).
Besides competing with NP for binding to VP30, RBBP6 also reduces the steadystate levels of VP30. RBBP6 is large protein that interacts with many cellular molecules and performs multiple functions, including its role as a ubiquitin E3 ligase (Chibi et al., 2008) . It has been shown that ubiquitination of YB-1 by RBBP6 results in the degradation of YB-1 in the proteasome (Chibi et al., 2008) and that RBBP6 can promote the interaction between p53 and the ubiquitin E3 ligase Hdm2 (Li et al., 2007) . The latter interaction allows p53 to be ubiquitinated by Hdm2, which in turn promotes the degradation of p53 in the proteasome (Li et al., 2007) . While the exact mechanism of how the steady-state levels of VP30 are modulated by RBBP6 is not entirely clear, it is tempting to postulate that RBBP6-VP30 interaction leads to the ubiquitination, either directly by RBBP6 or indirectly by recruiting another ubiquitin E3 ligase, and subsequent degradation of VP30. As a result, any viral function that requires VP30 could be negatively impacted. Future studies should address whether VP30 is in fact being ubiquitinated and whether RBBP6 is the responsible E3 ligase. Interestingly, Batra et al. show that RBBP6 could also specifically reduce the steady-state levels of the mRNA transcript of VP30, although the mechanism is not clear. Thus, the mechanisms of RBBP6 as an antiviral restriction factor are yet to be fully revealed.
VP30 and the VP30-binding motif PPxPxY on NP are highly conserved across the filovirus family. Based on this observation, Batra et al. demonstrate that RBBP6 could target VP30 from several other members of the filovirus family, including Reston virus, Lloviu virus, and Marburg virus. Therefore, RBBP6 is likely to be a pan-filovirus restriction factor. From an evolutionary perspective, it is quite intriguing to consider why and how humans have evolved such a restriction factor to target filoviruses. Since filoviruses are not known to circulate in human populations, it is unclear where the evolutionary selection pressure for RBBP6 to develop antifilovirus activity is derived. Nonetheless, several plausible hypotheses exist, including but not limited to (1) that filovirus has a long history in human populations and (2) that antifilovirus function is a byproduct of one of the cellular functions of RBBP6 that involves the PPxPxY motif. In-depth characterization of RBBP6 will be the key to understand how its antifilovirus function is evolved. However, it remains to be explored whether RBBP6 represents a one-of-a-kind mimicry or whether mimicry is a common antiviral approach. This work opens the door for future studies to investigate whether human cells employ viral mimicry to target other viruses.
The important discovery of RBBP6 as an antiviral restriction factor by Batra et al. was made possible by affinity tag-purification mass spectrometry, which has been successfully applied to characterize virus-host interactome for a variety of human-infecting viruses (Jean Beltran et al., 2017) . In fact, also in this issue, Shah et al. present another elegant virus-host interactome analysis on two members of flavivirus, namely Dengue virus and Zika virus (Shah et al., 2018) . Virus-host interactome studies generate a rich amount of information but each hit requires in-depth biochemical and biophysical characterization to probe specific interactions. While this may be an arduous task, mechanistic studies based on discoveries from virushost interactome analyses are likely to continue leading to exciting findings, as exemplified by RBBP6. Interaction of VP30 and NP promotes viral RNA synthesis. RBBP6 can outcompete NP for binding to VP30, since RBBP6 has a 5-fold higher binding affinity than NP (Batra et al., 2018) . RBBP6-VP30 interaction hampers viral replications through multiple mechanisms.
